Somatostatin receptor subtype-4 agonist NNC 26-9100 mitigates the effect of soluble Aβ42 oligomers via a metalloproteinase-dependent mechanism

Brain Research

Volumn 1520, Issue , 2013, Pages 145-156

  Sandoval, Karin E ^a   Farr, Susan A ^b,c   Banks, William A ^d,e   Crider, Albert M ^a   Morley, John E ^c   Witt, Ken A ^a  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloid beta oligomer; NNC 26 9100; Phosphoramidon; Somatostatin receptor subtype 4

Indexed keywords

1 [3 [N (5 BROMO 2 PYRIDYL) N (3,4 DICHLOROBENZYL)AMINO]PROPYL] 3 [3 (4 IMIDAZOLYL)PROPYL]THIOUREA; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; METALLOPROTEINASE; PHOSPHORAMIDON; SOMATOSTATIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL FRACTIONATION; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYMATIC DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOTSHOCK; INTRACELLULAR MEMBRANE; LEARNING; LONG TERM CARE; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; TREATMENT DURATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMINOPYRIDINES; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; MALE; MAZE LEARNING; METALLOPROTEASES; MICE; MICE, TRANSGENIC; RECEPTORS, SOMATOSTATIN; THIOUREA;

MUS MUSCULUS;

EID: 84879175747     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.05.006     Document Type: Article

References (53)

1. G.M. Aldridge, D.M. Podrebarac, W.T. Greenough, and I.J. Weiler The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting J. Neurosci. Methods 172 2008 250 254
2. Alzheimer's Association Alzheimer's disease facts and figures Alzheimers Dement 8 2012 131 168
3. M. Ankersen, A.M. Crider, S. Liu, B. Ho, H.S. Andersen, and C.E. Stidsen Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity JACS. 120 1998 1368 1373
4. J.F. Bruno, Y. Xu, J. Song, and M. Berelowitz Molecular cloning and functional expression of a brain-specific somatostatin receptor Proc. Nat. Acad. Sci. U.S.A. 89 1992 11151 11155
5. C. Casas, N. Sergeant, J.M. Itier, V. Blanchard, O. Wirths, N. van der Kolk, V. Vingtdeux, E. van de Steeg, G. Ret, T. Canton, H. Drobecq, A. Clark, B. Bonici, A. Delacourte, J. Benavides, C. Schmitz, G. Tremp, T.A. Bayer, P. Benoit, and L. Pradier Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model Am. J. Pathol. 165 2004 1289 1300
6. A.M. Crider, S. Liu, T. Li, S. Mahajan, M. Ankersen, and C.E. Stidsen Somatostatin receptor subtype 4 (sst4) ligands: synthesis and evaluation of indol-3-yl- and 2-pyridyl-thioureas Lett. Drug Des. Discovery 1 2004 84 87
7. R. Deane, R.D. Bell, A. Sagare, and B.V. Zlokovic Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease CNS Neurol. Disord. Drug. Targets 8 2009 16 30
8. E.A. Eckman, D.K. Reed, and C.B. Eckman Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme J. Biol. Chem. 276 2001 24540 24548
9. E.A. Eckman, S.K. Adams, F.J. Troendle, B.A. Stodola, M.A. Kahn, A.H. Fauq, H.D. Xiao, K.E. Bernstein, and C.B. Eckman Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme J. Biol. Chem. 281 2006 30471 30478
10. J. Epelbaum, J.L. Guillou, F. Gastambide, D. Hoyer, E. Duron, and C. Viollet Somatostatin, Alzheimer's disease and cognition: an old story coming of age? Prog. Neurobiol. 2009
11. S.A. Farr, W.A. Banks, K. Uezu, F.S. Gaskin, and J.E. Morley DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice Life Sci. 75 2004 2775 2785
12. L. Gimenez-Llort, G. Blazquez, T. Canete, B. Johansson, S. Oddo, A. Tobena, F.M. LaFerla, and A. Fernandez-Teruel Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid Neurosci. Biobehav. Rev. 31 2007 125 147
13. G.K. Gouras, J. Tsai, J. Naslund, B. Vincent, M. Edgar, F. Checler, J.P. Greenfield, V. Haroutunian, J.D. Buxbaum, H. Xu, P. Greengard, and N.R. Relkin Intraneuronal Abeta42 accumulation in human brain Am. J. Pathol. 156 2000 15 20
14. K.A. Gyure, R. Durham, W.F. Stewart, J.E. Smialek, and J.C. Troncoso Intraneuronal abeta-amyloid precedes development of amyloid plaques in down syndrome Arch. Pathol. Lab. Med. 125 2001 489 492
15. L.R. Hanson, D. Hafez, A.L. Svitak, R.B. Burns, X. Li, W.H. Frey 2nd, and R.A. Marr Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice J. Mol. Neurosci. 43 2011 424 427
16. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, and G. Cole Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice Science 274 1996 99 102
17. S.M. Huang, A. Mouri, H. Kokubo, R. Nakajima, T. Suemoto, M. Higuchi, M. Staufenbiel, Y. Noda, H. Yamaguchi, T. Nabeshima, T.C. Saido, and N. Iwata Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function J. Biol. Chem. 281 2006 17941 17951
18. N. Iwata, M. Higuchi, and T.C. Saido Metabolism of amyloid-beta peptide and Alzheimer's disease Pharmacol. Ther. 108 2005 129 148
19. B. Jeynes, and J. Provias The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease J. Neurosci. Res. 89 2011 22 28
20. H. Kanemitsu, T. Tomiyama, and H. Mori Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form Neurosci. Lett. 350 2003 113 116
21. U. Kumar Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis Neuroscience 134 2005 525 538
22. T.A. Lanz, and J.B. Schachter Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain J. Neurosci. Methods 157 2006 71 81
23. M.E. Larson, and S.E. Lesne Soluble Abeta oligomer production and toxicity J. Neurochem. 120 Suppl 1 2012 125 139
24. S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, and K.H. Ashe A specific amyloid-beta protein assembly in the brain impairs memory Nature 440 2006 352 357
25. L.F. Lue, Y.M. Kuo, A.E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J.H. Kurth, R.E. Rydel, and J. Rogers Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862
26. H. Ma, S. Lesne, L. Kotilinek, J.V. Steidl-Nichols, M. Sherman, L. Younkin, S. Younkin, C. Forster, N. Sergeant, A. Delacourte, R. Vassar, M. Citron, P. Kofuji, L.M. Boland, and K.H. Ashe Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity Proc. Nat. Acad. Sci. U.S.A. 104 2007 8167 8172
27. C.L. Masters, and D.J. Selkoe Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease Cold Spring Harb Perspect Med. 2 2012 a006262
28. K.G. Mawuenyega, W. Sigurdson, V. Ovod, L. Munsell, T. Kasten, J.C. Morris, K.E. Yarasheski, and R.J. Bateman Decreased clearance of CNS beta-amyloid in Alzheimer's disease Science 330 2010 1774
29. C.A. McLean, R.A. Cherny, F.W. Fraser, S.J. Fuller, M.J. Smith, K. Beyreuther, A.I. Bush, and C.L. Masters Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46 1999 860 866
30. L.N. Moller, C.E. Stidsen, B. Hartmann, and J.J. Holst Somatostatin receptors Biochim. Biophys. Acta 1616 2003 1 84
31. C. Mori, E.T. Spooner, K.E. Wisniewsk, T.M. Wisniewski, H. Yamaguch, T.C. Saido, D.R. Tolan, D.J. Selkoe, and C.A. Lemere Intraneuronal Abeta42 accumulation in down syndrome brain Amyloid 9 2002 88 102
32. J.E. Morley, V.B. Kumar, A.E. Bernardo, S.A. Farr, K. Uezu, N. Tumosa, and J.F. Flood Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory Peptides 21 2000 1761 1767
33. J.E. Morley, H.J. Armbrecht, S.A. Farr, and V.B. Kumar The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer's disease Biochim. Biophys. Acta 1822 2012 650 656
34. J.E. Morley, S.A. Farr, V.B. Kumar, and H.J. Armbrecht The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease Curr. Pharm. Des. 18 2012 1123 1130
35. L. Mucke, E. Masliah, G.Q. Yu, M. Mallory, E.M. Rockenstein, G. Tatsuno, K. Hu, D. Kholodenko, K. Johnson-Wood, and L. McConlogue High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation J. Neurosci. 20 2000 4050 4058
36. N.N. Nalivaeva, C. Beckett, N.D. Belyaev, and A.J. Turner Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J. Neurochem. 120 Suppl. 1 2012 167 185
37. A.J. Newell, L.I. Sue, S. Scott, P.K. Rauschkolb, D.G. Walker, P.E. Potter, and T.G. Beach Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid Neurosci. Lett. 350 2003 178 180
38. S. Oddo, A. Caccamo, J.D. Shepherd, M.P. Murphy, T.E. Golde, R. Kayed, R. Metherate, M.P. Mattson, Y. Akbari, and F.M. LaFerla Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction Neuron 39 2003 409 421
39. T. Saido, and M.A. Leissring Proteolytic degradation of amyloid beta-protein Cold Spring Harb Perspect Med. 2 2012 a006379
40. T. Saito, N. Iwata, S. Tsubuki, Y. Takaki, J. Takano, S.M. Huang, T. Suemoto, M. Higuchi, and T.C. Saido Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation Nat. Med. 11 2005 434 439
41. K.E. Sandoval, S.A. Farr, W.A. Banks, M.L. Niehoff, J.E. Morley, A.M. Crider, and K.A. Witt Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice Eur. J. Pharmacol. 654 2011 53 59
42. K.E. Sandoval, S.A. Farr, W.A. Banks, A.M. Crider, J.E. Morley, and K.A. Witt Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular Abeta(1-42) trimers Eur. J. Pharmacol. 2012
43. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav. Brain Res. 192 2008 106 113
44. D.J. Selkoe Resolving controversies on the path to Alzheimer's therapeutics Nat. Med. 17 2011 1060 1065
45. A. Serrano-Pozo, M.P. Frosch, E. Masliah, and B.T. Hyman Neuropathological alterations in Alzheimer disease Cold Spring Harb Perspect Med. 1 2011 a006189
46. K. Shirotani, S. Tsubuki, N. Iwata, Y. Takaki, W. Harigaya, K. Maruyama, S. Kiryu-Seo, H. Kiyama, H. Iwata, T. Tomita, T. Iwatsubo, and T.C. Saido Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases J. Biol. Chem. 276 2001 21895 21901
47. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen, and R. Katzman Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30 1991 572 580
48. K. Tomobe, and Y. Nomura Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence Neurochem. Res. 34 2009 660 669
49. M. Townsend, G.M. Shankar, T. Mehta, D.M. Walsh, and D.J. Selkoe Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers J. Physiol. 572 2006 477 492
50. A.J. Turner, L. Fisk, and N.N. Nalivaeva Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration Ann. N.Y. Acad. Sci. 1035 2004 1 20
51. C. Welinder, and L. Ekblad Coomassie staining as loading control in Western blot analysis J. Proteome Res. 10 2011 1416 1419
52. Y. Zhang, J.S. He, X. Wang, J. Wang, F.X. Bao, S.Y. Pang, F. Yin, H.G. Hu, X.L. Peng, W.M. Sun, Y.P. Zheng, L.L. Hou, and T. Hong Administration of amyloid-beta42 oligomer-specific monoclonal antibody improved memory performance in SAMP8 mice J. Alzheimers Dis. 23 2011 551 561
53. A. Zupa-Fernandez, A.M. Rozzi, H.M. Arnold, K.M. Felsenstein, A. Rowley, G. Treton, and G. Yohrling Society for Neuroscience Optimization of soluble amyloid beta extraction from non-transgenic rodents to facilitate the testing of gamma-secretase modulators 37 2007 Society for Neuroscience San Diego